ZIOPHARM Oncology Inc (NASDAQ:ZIOP) was downgraded by ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Friday.

Several other equities analysts have also weighed in on ZIOP. BidaskClub upgraded shares of ZIOPHARM Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, August 8th. HC Wainwright set a $10.00 target price on shares of ZIOPHARM Oncology and gave the company a “buy” rating in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $13.17.

Shares of ZIOPHARM Oncology (ZIOP) traded up 3.67% during mid-day trading on Friday, reaching $6.21. 1,985,023 shares of the company’s stock traded hands. The stock’s market capitalization is $873.32 million. The company’s 50-day moving average price is $5.82 and its 200-day moving average price is $6.25. ZIOPHARM Oncology has a 12-month low of $4.84 and a 12-month high of $7.88.

ZIOPHARM Oncology (NASDAQ:ZIOP) last posted its earnings results on Monday, July 31st. The biotechnology company reported ($0.13) earnings per share for the quarter, meeting the consensus estimate of ($0.13). The firm had revenue of $1.60 million during the quarter, compared to analyst estimates of $1.66 million. The business’s revenue for the quarter was down 5.9% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($1.01) earnings per share. Analysts anticipate that ZIOPHARM Oncology will post ($0.56) earnings per share for the current year.

WARNING: “ZIOPHARM Oncology Inc (ZIOP) Downgraded to Sell at ValuEngine” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.americanbankingnews.com/2017/09/16/ziopharm-oncology-inc-ziop-downgraded-to-sell-at-valuengine.html.

Hedge funds have recently modified their holdings of the company. Amalgamated Bank lifted its holdings in shares of ZIOPHARM Oncology by 12.9% in the 2nd quarter. Amalgamated Bank now owns 16,807 shares of the biotechnology company’s stock worth $105,000 after acquiring an additional 1,924 shares during the last quarter. Mission Wealth Management LLC acquired a new position in shares of ZIOPHARM Oncology in the 1st quarter worth approximately $108,000. Oppenheimer & Co. Inc. lifted its holdings in shares of ZIOPHARM Oncology by 50.0% in the 2nd quarter. Oppenheimer & Co. Inc. now owns 18,000 shares of the biotechnology company’s stock worth $112,000 after acquiring an additional 6,000 shares during the last quarter. BB&T Securities LLC acquired a new position in shares of ZIOPHARM Oncology in the 2nd quarter worth approximately $112,000. Finally, Principal Financial Group Inc. lifted its holdings in shares of ZIOPHARM Oncology by 7.5% in the 2nd quarter. Principal Financial Group Inc. now owns 24,046 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 1,673 shares during the last quarter. Hedge funds and other institutional investors own 41.94% of the company’s stock.

ZIOPHARM Oncology Company Profile

ZIOPHARM Oncology, Inc is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for ZIOPHARM Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.